Microba Life Sciences (FRA:F3Y) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:F3Y Microba Life Sciences Ltd FRA:F3Y
29 GF Score
Price €0.02
GF Value €0.12
! 6 Warning Signs
View Full Analysis

What is Microba Life Sciences FFO per Share?

FFO per Share only applies to REITs.

FRA:F3Y
29GF Score
Microba Life Sciences Ltd FRA:F3Y
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Microba Life Sciences (FRA:F3Y) Overvalued in 2026?

Based on GuruFocus' analysis, Microba Life Sciences stock appears to be undervalued. The current stock price of €0.02 is trading 81.3% below its estimated GF Value™ of €0.12.

Key valuation signals for FRA:F3Y:

  • FFO per Share:
  • GF Value™: €0.12 vs. price of €0.02 (81.3% below fair value)
  • GF Score™: 29/100 with 6 warning signs

No single metric tells the full story. See the FRA:F3Y stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Microba Life Sciences Business Description

Other Exchanges MAP:Australia
Address 324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are: Testing Services and Supplements, which derive key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
29GF Score

Get the complete analysis for FRA:F3Y

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.12
GF Value